Blue bin 0175 whirred along a conveyer belt in Fairview Health Services’ new automated pharmacy in Shoreview with a big job: ...
Time In the Market on MSN
Hims & Hers Q4 2025 earnings: Growth amidst regulatory crosswinds
Analysis of Hims & Hers Q4 2025 results, GLP-1 compounding risks, labs, and the $1.15B Eucalyptus acquisition.
Popular weight-loss drugs, including Ozempic, Wegovy, Trulicity and Mounjaro, produced by independent pharmacy labs, sickened ...
The compounds have exploded in popularity, but big questions about safety and effectiveness are still unresolved.
Demand from patients for obesity medication is unrelenting. So, too, is the battle over who gets to develop and distribute ...
The latest wellness craze involves injecting these molecules for athletic performance, longevity and more. Scientists say the ...
Make sure the clinician knows what other medications you’re taking, and set up a real follow-up plan to adjust these ...
Indiana lawmakers are weighing new guardrails around drug compounding amid warnings that patients are receiving powerful ...
The recent withdrawal of Hims & Hers’ GLP-1 pill raises questions about the safety and effectiveness of compounded medications ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results